Celldex Therapeutics reported $782.35M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Celldex Therapeutics USD 782.35M 271.09M Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Northwest Biotherapeutics USD 80.05M 49.44M Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026